

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)



(10) International Publication Number
WO 2023/064753 A1

(51) International Patent Classification:

G01N 33/543 (2006.01) *A61M 1/34* (2006.01)
B01D 15/38 (2006.01) *A61M 1/36* (2006.01)
B01D 61/02 (2006.01) *G01N 33/53* (2006.01)
G01N 33/569 (2006.01) *G01N 33/566* (2006.01)

(21) International Application Number:

PCT/US2022/077885

(22) International Filing Date:

10 October 2022 (10.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/262,487 13 October 2021 (13.10.2021) US
63/321,983 21 March 2022 (21.03.2022) US

(71) Applicant: **AETHLON MEDICAL, INC.** [US/US];
11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 (US).

(72) Inventors: **FISHER, JR., Charles J.**; 2164 Cambridge Avenue, Cardiff-by-the-Sea, California 92007 (US). **CAMPION, Rosalia De Necochea**; 2301 Mesa Drive, Ocean-side, California 92054 (US). **LAROSA, Steven P.**; 14747 Gail Park Lane, Poway, California 92604 (US). **MARLEAU, Annette**; c/o Aethlon Medical, Inc., 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 (US). **JACOBS, Michael**; c/o Aethlon Medical, Inc., 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 (US).

(74) Agent: **FURMAN, Eric S.**; KNOBBE MARTENS OLSON & BEAR LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).

(54) Title: DEVICES AND METHODS FOR TREATING A VIRAL INFECTION AND SYMPTOMS THEREOF




FIG. 21

(57) Abstract: The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post COVID-19 syndrome or similar post-disease sequelae symptoms of COVID-19 or similar disease. The present invention provides a lectin based extracorporeal methods for binding and physically removing SARS-CoV-2 virions, or fragments thereof such as SARS-Co V-2-derived glycoproteins, from the circulatory system, thereby reducing viral load in infected blood. The present invention also provides lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles, such as exosomes containing SARS-Co V-2-derived glycoproteins and/or other biological molecules from the circulatory system, thereby reducing the severity of the disease.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*